Equus Total Return, Inc. (EQS) · Oct 13, 2026 · Other events

Equus Total Return gets NYSE warning as sub-$1 price persists

$1 listing deficiency — 30-day average closing price below $1.00; six-month cure period

Equus Total Return received an NYSE listing-deficiency notice after its average share price stayed below $1. The stock remains listed, but a cure is required.

Equus is trying to transition from a business development company into an operating company, but its immediate problem is maintaining the NYSE platform needed for that strategy. The company says it is evaluating an acquisition or merger with an operating business to end its BDC status, making continued exchange access more than a technical detail.

The filing confirms a genuine listing deficiency, not an imminent delisting. Equus was notified that its average closing price fell below the NYSE’s $1.00 minimum for 30 consecutive trading days. The shares remain listed and trading for now, with a six-month window to restore both the month-end closing price and the trailing 30-day average to at least $1.00.

The practical response may involve shareholder-approved capital-structure action. Equus says it will consider several remedies, explicitly including a reverse stock split. 〔0〕 That does not change the operating business today, but it adds execution risk and could complicate the company’s broader effort to reposition itself.

Bottom line: This is not a delisting, but it is a new warning that Equus’s weak share price has become a business constraint. The immediate story is a compliance timetable, with a reverse split now a live possibility rather than a remote theoretical remedy.,

What to watch next

Cure plan due to NYSE by October 20, 2026

Original filing on SEC EDGAR

Equus Total Return gets NYSE warning as sub-$1 price persists | EQS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.